NEW YORK — Flatiron Health has appointed Nathan Hubbard as its new chief executive officer, succeeding Carolyn Starrett, who will transition to a senior advisor role after leading the oncology-focused health technology company since 2021.
Hubbard, who has more than 20 years of leadership experience in biopharma, healthcare, and data-driven businesses, previously built Flatiron’s international business, expanded partnerships with major biopharma companies, and helped shape the company’s strategic vision. He will now guide Flatiron through its next phase of growth in cancer research and care innovation.
“I understand the critical role Flatiron plays in accelerating cancer research and improving care,” Hubbard said. “I’m committed to building on the strong foundation Carolyn and the team have created.”
During her tenure, Starrett oversaw major growth, expanding Flatiron’s real-world data platform from 400,000 to more than 5.5 million patients, launching an evidence services business, and scaling its research network to over 30 sites in the U.K., Germany, and Japan. She also led the growth of OncoEMR® to serve over 4,500 U.S. providers and nearly doubled the company’s revenue run rate.
Roche CEO Thomas Schinecker, whose company is a long-time Flatiron partner, praised the leadership change, saying Hubbard’s “entrepreneurial drive” and alignment with the company’s mission make him well-suited to lead its future efforts in oncology innovation.
